ClinicalTrials.gg
AvailableNCT07603401Updated Nov 18, 2026

Expanded Access Program of Bitopertin For Participants With EPP or XLP

An expanded access record providing DISC-1459 in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Disc Medicine, Inc. Available at 9 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Disc Medicine, Inc · Expanded access

How we know

Updated Nov 18, 20264 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Other kind
Only one
of the 18
Registered
17th of 18
by date
Lead sponsor
4 of 18
Disc Medicine, Inc

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the only one of another kind, and was the 17th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory treatment options available in the US and to learn if bitopertin is safe to treat EPP and XLP.

03

Conditions studied

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)

Keywords

  • EPP
  • XLP
  • DISC-1459
  • RO4917838
  • Porphyria
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (and assent where applicable).
  • Age ≥12 years at time of request.
  • Diagnosis of erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), confirmed by ferrochelatase (FECH) or aminolevulinic acid synthase 2 (ALAS2) genotyping or by biochemical porphyrin analysis. Prior confirmation is acceptable; re-testing is not required if documentation of prior diagnosis is available.
  • ≥10 g/dL at baseline.
  • Females of must have a negative pregnancy test prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Known to bitopertin or its .
  • Patients with or ALT ≥3 × (ULN), or total ≥2 × ULN (unless due to Gilbert syndrome), or albumin below the lower limit of normal at screening.
  • Patients with a history of liver transplantation or anticipated need for liver transplantation.
  • Pregnancy, planned pregnancy during the program, or breastfeeding.
  • Inability or unwillingness to comply with requirements.
  • Use of any of the following prohibited concomitant therapies:

    • Strong inhibitors
    • Strong CYP3A4 inducers
    • Grapefruit or Seville orange products
    • Afamelanotide or dersimelagon
    • Chronic opioid therapy (>7 consecutive days)
  • Patients who are currently participating in a bitopertin clinical study.
  • Patients who previously participated in a bitopertin study and discontinued the study due to an adverse event or for reasons that, in the judgement of the treating physician or Disc, would put the patient at unacceptable risk or otherwise preclude participation in the EAP.
  • Patients who have received another therapy within 30 days.
  • History of suicidal ideation with intent (C-SSRS Grade 4 or 5) within the past year or suicidal behavior within the past 5 years.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

06

Where to request access

9 of 9 sites recruiting
  • University of Miami Miller School of Medicine
    Miami, Florida 33146, United States
    Available
    • Cynthia Levy, M.D. · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
    Available
    • Amy Yeung · Principal investigator
  • MetroBoston Clinical Partners
    Boston, Massachusetts 02135, United States
    Available
    • Mark S Amster, M.D. · Principal investigator
  • Henry Ford Health
    Detroit, Michigan 48202, United States
    Available
    • Tasneem Mohammad, M.D. · Principal investigator
  • Mount Sinai Hospital
    New York, New York 10029, United States
    Available
    • Manisha Balwani, M.D. · Principal investigator
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
    Available
    • Sean Rudnick · Principal investigator
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Available
    • Angelika Erwin, MD, PhD · Principal investigator
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
    Available
    • Akshata Moghe, MD, PhD · Principal investigator
  • University of Washington
    Seattle, Washington 98195, United States
    Available
    • Sioban Keel, MD · Principal investigator
07

Updates

3 registry updates since Sep 25, 2026
Sites
4 sites added
Show 4 added (4 United States)
  • Henry Ford Health · Detroit, United States
  • The Cleveland Clinic Foundation · Cleveland, United States
  • The University of Texas Health Science Center at Houston · Houston, United States
  • University of Washington · Seattle, United States
across 3 updates, Oct 6, 2026 – Nov 18, 2026
Show all 3 updates
  1. Nov 18, 2026
    1 site added
    Show site
    • University of Washington · Seattle, United States
  2. Nov 5, 2026
    1 site added
    Show site
    • The University of Texas Health Science Center at Houston · Houston, United States
  3. Oct 6, 2026
    2 sites added
    Show 2 added (2 United States)
    • Henry Ford Health · Detroit, United States
    • The Cleveland Clinic Foundation · Cleveland, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT07603401
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
May 22, 2026
Last update
Nov 18, 2026

Study contacts

Disc Medicine Clinical Trials
Contact
Clinicaltrials@discmedicine.com
(617) 674 9274
Will Savage, MD, PhD
study director · Disc Medicine
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion